CompletedPhase 4NCT01637558

Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)

Studying Tuberculosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Cape Town
Principal Investigator: Helen M McIlleron, PhD
University of Cape Town
Intervention: 8 hourly LPV/r during TB treatment(drug)
Enrollment: 200 enrolled
Eligibility: 12 years · All sexes
Timeline: 2012 – 2017

Study locations (4)

Queen Elizabeth Central Hospital, Blantyre, Malawi
Red Cross Childrens Hospital, Cape Town, Western Cape, South Africa
KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town, Western Cape, South Africa
Desmond Tutu Centre, Cape Town, Western Cape, South Africa

Collaborators

Liverpool School of Tropical Medicine · Uppsala University · University of North Carolina

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01637558 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials